Latest Biotech News

Bristol Myers Squibb terminated its $380 million collaboration with cell-therapy manufacturing startup Cellares, setting off a restructuring at the CDMO. The parties cited Breyanzi (lisocabtagene...

SK Biopharmaceuticals agreed to acquire global commercialization rights to Biohaven’s opakalim (BHV-7000) in an up-to-$795 million deal, extending SK Life Science’s epilepsy franchise alongside...

McKesson signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion in an all-cash transaction. The deal is designed to expand McKesson’s oncology and clinical...

A real-world study found that sustained Zepbound (tirzepatide) use in adults over age 55 with obesity was associated with lower healthcare costs, alongside reduced hospital admissions and...

Guardant Health is collecting real-world validation data for its Shield-linked multi-cancer detection (MCD) blood test, with the company aiming to refine performance and prepare for potential...

In a phase 3 trial dubbed SYNCHRONIZE-1, survodutide—an investigational GLP-1 receptor–glucagon dual agonist—produced significantly greater weight loss than placebo in adults with obesity without...

The US Federal Trade Commission filed an amicus brief arguing that licensing of pending patents can pose an antitrust risk, pointing to how Amgen’s exclusive rights to two etanercept-related...

Kite Pharma, a Gilead company, described a new cytometry technique intended to characterize individual lentiviral vector particles for in vivo CAR T therapy development. The approach uses flow...

Onos Health raised $17 million in a Series A round to expand its AI-powered behavioral health platform. The round was led by Costanoa with participation from Flare Capital Partners and CVS Health...

The FDA approved Revolution Medicines’ oral pan-RAS inhibitor daraxonrasib (Rasonque) for advanced pancreatic ductal adenocarcinoma, positioning it as a new treatment option based on survival...

SK Biopharmaceuticals agreed to acquire commercial rights to Biohaven’s late-stage epilepsy candidate opakalim (BHV-7000) in a $795 million deal, handing the program to a partner with established...

Boehringer Ingelheim’s investigational dual GLP-1/glucagon receptor agonist survodutide produced significantly greater weight reduction than placebo in a Phase 3 trial in adults with obesity...

A new industry focus has emerged on sterilization as biomanufacturing scales—arguing that steam-in-place systems remain a major constraint on capacity, cost, and plant siting even as single-use...

The EVER trial reported 12-month outcomes after early mobilization in patients with sepsis and respiratory failure, finding that starting movement earlier did not translate into better longer-term...

Janssen’s phase I/IIa MajesTEC-9 trial reported major efficacy results for teclistamab, a BCMA- and CD3-targeting T-cell engager, in refractory multiple myeloma. The program met its primary...

The FDA cleared Roche and Eli Lilly’s Elecsys pTau217 blood test to support assessments that can rule in and rule out Alzheimer’s disease in people age 55 and older with signs of cognitive...

Kite Pharma (a Gilead company) described a new approach to characterize individual lentiviral vector particles using flow virometry, targeting deeper batch consistency assessment for...

A study in Nature Aging reported that cGAS-deficient mice show signs of premature aging alongside increased activity of LINE1 repetitive elements and inflammation. The findings connect a key...

Mass General Brigham investigators used artificial intelligence to link incidental radiation exposure to the thymus with poorer outcomes in patients treated for locally advanced non-small cell...

The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for advanced pancreatic ductal adenocarcinoma, marking the first approved RAS inhibitor for this indication. The approval covers...